Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 5/20 | 1.00 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 1.00 |
| ▸ | GLB1 | P16278 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 5/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GANAB | Q14697 | 1/20 | 0.46 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.46 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyfuconojirimycin SCHEMBL15686574 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876082 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL4378188 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL1867289 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL12581516 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL9999893 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13328524 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL15691930 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL13876087 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA | |
| Deoxyfuconojirimycin SCHEMBL2435560 | 1.00 | FUCA1 (1.00) | FUCA1FUCA2GLB1GBA1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | FUCA1 17/4885FUCA2 18/4885GLB1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.